Actively Recruiting
Evaluating Safety, Pharmacokinetics, and Preliminary Efficacy of HEC-921 Injection Alone and with Other Cancer Therapies in Advanced Malignant Solid Tumors
Led by Sunshine Lake Pharma Co., Ltd. · Updated on 2026-09-24
110
Participants Needed
1
Research Sites
35 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase I open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of HEC-921 injection. This study involves patients with advanced malignant solid tumors and aims to determine the recommended Phase II dose based on these factors. The research is also assessing HEC-921 alone and in combination with other antineoplastic therapies. Participants may receive HEC-921 via intravenous infusion either as monotherapy or combined with capecitabine, oxaliplatin, and bevacizumab. Capecitabine is taken orally twice daily for 14 days, while oxaliplatin and bevacizumab are administered intravenously on Day 1. The study includes dose escalation and expansion phases, with specific criteria for tumor markers to guide treatment. Treatment dosing and combinations depend on the study phase and participant condition. During the study, participants will be monitored for dose-limiting toxicities over 21 days after the first HEC-921 dose and adverse events for up to one year. Researchers will measure tumor response, disease control, progression-free and overall survival, and a comprehensive set of pharmacokinetic and immunogenicity markers. Assessments include imaging, laboratory tests, and safety evaluations throughout treatment and follow-up, which may last up to one year after dosing.
CONDITIONS
Brief Title
HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors
Research Team
L
Liu Tianshu, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here